Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024
15 Maio 2024 - 2:00AM
Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and
Operational Progress on May 23, 2024
Vivoryon Therapeutics N.V. to Report Q1
2024 Financial Results and Operational Progress on May 23,
2024
Halle (Saale) / Munich, Germany,
May 15, 2024 - Vivoryon Therapeutics N.V.
(Euronext Amsterdam: VVY; NL00150002Q7)
(Vivoryon), a clinical stage company focused on
the discovery and development of small molecule medicines to
modulate the activity and stability of pathologically altered
proteins, today announced that it will publish its first quarter
financial results for the period ended March 31, 2024 and provide a
corporate update on Thursday, May 23, 2024. The Company will
host a conference call and webcast open to the public.
Conference call detailsDate: May 23, 2024Time:
3:00 pm CEST / 9:00 am EDTThe conference call will be available via
phone and webcast. The live audio webcast of the call will be
available on Vivoryon´s website at:
https://www.vivoryon.com/investors-news/news-and-events/presentations-webcasts/
To join the conference call via phone, participants may
pre-register and will receive dedicated dial-in details to easily
and quickly access the call via the following website:
https://register.vevent.com/register/BI9aadfa99e014435493eca917a11150f1
It is suggested participants dial into the conference call 15
minutes prior to the scheduled start time to avoid any delays in
attendance.
###
About Vivoryon Therapeutics N.V.Vivoryon is a
clinical stage biotechnology company focused on developing
innovative small molecule-based medicines. Driven by its passion
for ground-breaking science and innovation, the Company strives to
change the lives of patients in need suffering from severe
diseases. The Company leverages its in-depth expertise in
understanding post-translational modifications to develop medicines
that modulate the activity and stability of proteins which are
altered in disease settings. The Company has established a pipeline
of orally available small molecule inhibitors for various
indications including Alzheimer’s disease, inflammatory and
fibrotic disorders, including of the kidney, and
cancer. www.vivoryon.com.
Vivoryon Forward Looking StatementsThis press
release includes forward-looking statements, including, without
limitation, those regarding the business strategy, management plans
and objectives for future operations of Vivoryon Therapeutics N.V.
(the “Company”), estimates and projections with respect to the
market for the Company’s products and forecasts and statements as
to when the Company’s products may be available. Words such as
“anticipate,” “believe,” “estimate,” “expect,” “forecast,”
“intend,” “may,” “plan,” “project,” “predict,” “should” and “will”
and similar expressions as they relate to the Company are intended
to identify such forward-looking statements. These forward-looking
statements are not guarantees of future performance; rather they
are based on the Management’s current expectations and assumptions
about future events and trends, the economy and other future
conditions. The forward-looking statements involve a number of
known and unknown risks and uncertainties. These risks and
uncertainties and other factors could materially adversely affect
the outcome and financial effects of the plans and events described
herein. The Company’s results of operations, cash needs, financial
condition, liquidity, prospects, future transactions, strategies or
events may differ materially from those expressed or implied in
such forward-looking statements and from expectations. As a result,
no undue reliance should be placed on such forward-looking
statements. This press release does not contain risk factors.
Certain risk factors that may affect the Company’s future financial
results are discussed in the published annual financial statements
of the Company. This press release, including any forward-looking
statements, speaks only as of the date of this press release. The
Company does not assume any obligation to update any information or
forward-looking statements contained herein, save for any
information required to be disclosed by law.
For more information, please contact:
Investor ContactVivoryon Therapeutics N.V.Dr.
Manuela Bader, Director IR & CommunicationTel: +49 (0)345 555
99 30Email: IR@vivoryon.com
Media ContactTrophic CommunicationsValeria
FisherTel: +49 175 8041816Email: vivoryon@trophic.eu
Vivoryon Therapeut (EU:VVY)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Vivoryon Therapeut (EU:VVY)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
